Grant: Engage Grants Program
University of Toronto
$25,000.00
Development of abuse-deterrent nanotechnology formulation for effective pain management
EF 2014-15
Résumé
Altus Formulation Inc. is focused on the development of drug delivery technologies to generate cost effective 'safe to use' products to improve the lives of patients. Altus has developed an innovative series of amphiphilic and pH-sensitive block copolymers that can self-assemble in aqueous media to form nano-sized block copolymer micelles (BCMs) that entrap drugs within their cores and enable drug delivery. This proprietary series of block copolymers includes a poly(ethylene glycol) (PEG) hydrophilic block that forms the outer shell of the micelles and a core-forming, drug trapping block that is comprised of a random copolymer of polymethacrylate and poly(t-butyl methacrylate) (abbreviated: PMA). The nature of the PMA core-forming block is such that it retains the drug in a non-crystalline form and protects it during transit through the stomach; due to its pH sensitivity the PMA block allows site-specific release of the drug once in the small intestine where drug absorption is maximized. To this point, Altus has conducted pre-clinical studies demonstrating the ability of PEG-b-PMA copolymer micelles to effectively deliver hydrophobic anti-cancer drugs following oral administration. Altus is now interested in expanding the use of this promising series of materials to create proprietary formulations of active agents as oral controlled release liquids for effective pain management. Dr. Christine Allen is a world-renowned expert in the area of BCMs for drug delivery and, as a result, she is uniquely qualified to work with Altus Formulation on this challenging project. Indeed, the initial design and physico-chemical characterization of these formulations could lead to the creation of an entirely new product pipeline for this Canadian company. Furthermore, the PEG-b-PMA BCM formulation platform has the potential to result in significant improvements in outcomes for patients afflicted with acute and chronic pain.
Programme
Engage Grants Program
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
463179-2014
Name nom
Allen, Christine
Department département
Pharmacy, Leslie Dan Faculty of
Organization id
31
Institution établissement
University of Toronto
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2014
Competition year année de concours
2014
Award amount
25000
Program id
EGP
Program name en
Engage Grants Program
Program name fr
Programme de subventions d'engagement partenariat
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1553
Committee name en
Ontario Internal Decision Committee
Committee name fr
Comité de décision interne pour l'Ontario
Area of application code
1201
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Life sciences (including biotechnology)
Area of application fr
Sciences de la vie (y compris biotechnologie)
Research subject code
2004
Research subject group en
Materials science and technology
Research subject group fr
Science et technologie des matériaux
Research subject en
Polymers and coatings
Research subject fr
Polymères et revêtements
Partie
1
Nb partie
1
Application title
Development of abuse-deterrent nanotechnology formulation for effective pain management
Keyword
NSERC
Application summary
Altus Formulation Inc. is focused on the development of drug delivery technologies to generate cost effective 'safe to use' products to improve the lives of patients. Altus has developed an innovative series of amphiphilic and pH-sensitive block copolymers that can self-assemble in aqueous media to form nano-sized block copolymer micelles (BCMs) that entrap drugs within their cores and enable drug delivery. This proprietary series of block copolymers includes a poly(ethylene glycol) (PEG) hydrophilic block that forms the outer shell of the micelles and a core-forming, drug trapping block that is comprised of a random copolymer of polymethacrylate and poly(t-butyl methacrylate) (abbreviated: PMA). The nature of the PMA core-forming block is such that it retains the drug in a non-crystalline form and protects it during transit through the stomach; due to its pH sensitivity the PMA block allows site-specific release of the drug once in the small intestine where drug absorption is maximized. To this point, Altus has conducted pre-clinical studies demonstrating the ability of PEG-b-PMA copolymer micelles to effectively deliver hydrophobic anti-cancer drugs following oral administration. Altus is now interested in expanding the use of this promising series of materials to create proprietary formulations of active agents as oral controlled release liquids for effective pain management. Dr. Christine Allen is a world-renowned expert in the area of BCMs for drug delivery and, as a result, she is uniquely qualified to work with Altus Formulation on this challenging project. Indeed, the initial design and physico-chemical characterization of these formulations could lead to the creation of an entirely new product pipeline for this Canadian company. Furthermore, the PEG-b-PMA BCM formulation platform has the potential to result in significant improvements in outcomes for patients afflicted with acute and chronic pain.